PE-22-28
Neuropeptide
Also known as: spadin analog, shortened spadin (residues 22-28), TREK-1 inhibitor peptide
Evidence is limited to animal or in-vitro work. No human pharmacokinetics. Any human dose in circulation is extrapolated, and extrapolation across species routinely fails.
The primary source (Djillani et al., PMID 28955242 / PMC5601071) reports IMPROVED in-vivo stability vs spadin and TREK-1 inhibition (IC50 ~0.12 nM vs ~40 nM for spadin), plus antidepressant-like effects within 4 days in rodents. A specific numeric plasma half-life was not extracted; the widely-quoted 'up to 23 hours duration of action' could NOT be tied to a specific primary half-life measurement, flagged unverified. IC50 is a potency value, not a half-life.
Preclinical only; rodent studies dose by mg/kg (route typically IV/IP/SC in mice). No human dose exists. Do not translate to human mcg.
Rodent behavioral/neurogenesis data from the Mazella/Djillani group (Nice, France) showing antidepressant-like effects via TREK-1 blockade. Promising but preclinical and largely single-lineage; no human data.
Lyophilised: General peptide convention: -20 C (no compound-specific data).
Reconstituted: General convention: 2-8 C (no compound-specific data).
No human safety data. Preclinical only; do not infer human dosing or safety.